Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 16/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | SCD | O00767 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24954078 | 0.74 | MEN1 (0.31) | OGASMN1; SMN2 | |
| SCHEMBL24954275 | 0.73 | OGA (0.34) | OGASMN1; SMN2 | |
| SCHEMBL19920201 | 0.68 | GLS (0.50) | — | |
| SCHEMBL24953526 | 0.66 | SCD (0.50) | SMN1; SMN2SCD | |
| SCHEMBL24953816 | 0.63 | MEN1 (0.47) | — | |
| SCHEMBL4972075 | 0.59 | LMNA (0.53) | OGA | |
| SCHEMBL14987267 | 0.58 | GLS (0.56) | — | |
| SCHEMBL15043787 | 0.58 | GLS (0.57) | — | |
| SCHEMBL22957185 | 0.57 | OGA (0.67) | OGA | |
| SCHEMBL5653949 | 0.56 | CCNE1 (0.55) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230029266-A1 | MrgprX2 Antagonists for the Treatment of Inflammatory Disorders | DERMIRA, INC. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230029266-A1 | MrgprX2 Antagonists for the Treatment of Inflammatory Disorders | MRGPRX2, MRGPRX1, MRGPRX4 | OGA 1412/4885SMN1; SMN2 3817/4885SCD 2396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.